Quarterly ResultMay 13, 2026, 05:07 PM
Semnur Pharmaceuticals Q1 Net Loss $4.6M; $120M Financing Terminated
AI Summary
Semnur Pharmaceuticals reported a net loss of $4.6 million for the three months ended March 31, 2026, a significant increase from $0.7 million in the prior year. The company also disclosed the termination of two key financing agreements, the PIPE SPA and the Semnur/Biconomy SPA, which were expected to raise an aggregate of $120 million. Management has concluded that these conditions raise substantial doubt about the company's ability to continue as a going concern, citing dependence on Scilex for funding and the need for additional financing.
Key Highlights
- Terminated PIPE SPA and Semnur/Biconomy SPA, which aimed to raise $20 million and $100 million respectively.
- Management concluded substantial doubt about the company's ability to continue as a going concern.
- Net loss for Q1 2026 was $4.6 million, significantly up from $0.7 million in Q1 2025.
- Research and development expenses increased to $1.3 million in Q1 2026 from $0.2 million in Q1 2025.
- General and administrative expenses rose to $3.3 million in Q1 2026 from $0.5 million in Q1 2025.
- Accumulated deficit reached $280.4 million as of March 31, 2026.
- Cash and cash equivalents were $0.1 million as of March 31, 2026.
- Total liabilities increased to $27.3 million as of March 31, 2026.